Abstract: A wash buffer comprising a surfactant for use in affinity and cation exchange chromatography to purify proteins of interest from protein aggregates and to remove and/or inactivate viruses. When used during affinity or cation exchange chromatography for the purification of a protein of interest, such as an antibody, the wash buffer significantly improves viral clearance from the preparation, while also reducing the levels of host cell proteins and protein aggregates. Following affinity or cation exchange chromatography with the wash buffer, the protein of interest may be further purified using other chromatography and filtration operations.
Type:
Grant
Filed:
June 21, 2018
Date of Patent:
August 30, 2022
Assignee:
Cephalon, Inc.
Inventors:
Lu Wang, Albert Kao, Zhaoqing Zhang, Mi Jin, Tianyi Zhou
Abstract: Disclosed herein are human antibody molecules that immunospecifically bind to human CXCR2. The disclosed human antibody molecules are potent and selective antagonists of CXCR2 functions and prevent the recruitment of neutrophils into tissues without strongly depleting circulating neutrophil numbers. Pharmaceutical compositions, nucleic acid molecules, vectors, cells, and uses of the disclosed antibodies are also provided.
Type:
Grant
Filed:
July 31, 2019
Date of Patent:
May 17, 2022
Assignee:
Cephalon, Inc.
Inventors:
Doris Shim Siew Chen, Lynn Dorothy Poulton, Adam Clarke, David Jose Simon Laine, Matthew Pollard, Bridget Ann Cooksey, Anthony Doyle, Jason William Gill
Abstract: Recombinant antibodies that specifically bind to IL-15 as well as a complex of IL-15 and the IL-15 Receptor-alpha are provided. The antibodies inhibit immune cell proliferation, and are capable of use in the treatment of any autoimmune or inflammatory disease or condition where IL-15 is dysregulated, including Celiac disease.
Type:
Grant
Filed:
December 21, 2017
Date of Patent:
March 8, 2022
Assignee:
Cephalon, Inc.
Inventors:
David Jose Simon Laine, Matthew Pollard, Anthony Gerard Doyle, Lynn Dorothy Poulton, Adam William Clarke
Abstract: Disclosed herein are methods of treating severe glucocorticoid-dependent eosinophilic asthma in a subject whose asthma has been inadequately controlled with subcutaneously-administered mepolizumab. Also provided are methods of predicting responsiveness to anti-IL-5 antibody treatment in a subject having severe glucocorticoid-dependent eosinophilic asthma.
Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.
Type:
Grant
Filed:
October 18, 2018
Date of Patent:
January 11, 2022
Assignee:
Cephalon, Inc.
Inventors:
Lynn Dorothy Poulton, Matthew Pollard, Anthony G. Doyle, Bridget A. Cooksey, Vanya Pande, Adam W. Clarke
Abstract: Disclosed herein are fully human antibody molecules that immunospecifically bind to human IL-5. The antibody molecules can bind to human IL-5 with an equilibrium affinity constant (KD) of at least about 40 pM as determined by surface plasmon resonance.
Type:
Grant
Filed:
December 20, 2017
Date of Patent:
September 7, 2021
Assignee:
CEPHALON, INC.
Inventors:
Mark Terence Liddament, Anthony Doyle, Adam Clarke, David Jose Simon Laine, Bridget Ann Cooksey
Abstract: The disclosure provides compounds of Formula (I), wherein X, Y, and Z are defined herein. The disclosure also provides particles comprising one or more compounds described herein, compositions comprising one or more compounds or particles described herein and a pharmaceutically acceptable carrier, and methods of treating a subject in need thereof comprising administering one or more compounds, particles, or compositions described herein to the subject. X—Y—Z??(I).
Abstract: The present invention relates, in general, to polypeptides capable of transmigrating the blood-brain barrier, and uses thereof. More specifically, the present invention relates to polypeptides derived by site-directed mutagenesis of an existing antibody fragment and uses thereof, and methods of making such molecules. The polypeptides of the present invention show enhanced blood-brain barrier crossing and brain exposure levels in vitro and in vivo.
Type:
Grant
Filed:
December 12, 2017
Date of Patent:
February 2, 2021
Assignees:
National Research Council of Canada, Cephalon, Inc.
Inventors:
Danica Stanimirovic, Traian Sulea, Kristin Kemmerich, David Wilson, Jennifer Stratton, Matthew Pollard, Adam Clarke
Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
Type:
Grant
Filed:
October 26, 2018
Date of Patent:
April 28, 2020
Assignee:
CEPHALON, INC.
Inventors:
Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
Abstract: The present invention relates, in general, to polypeptides capable of transmigrating the blood-brain barrier, and uses thereof. More specifically, the present invention relates to polypeptides derived by site-directed mutagenesis of an existing antibody fragment and uses thereof, and methods of making such molecules. The polypeptides of the present invention show enhanced blood-brain barrier crossing and brain exposure levels in vitro and in vivo.
Type:
Application
Filed:
December 12, 2017
Publication date:
March 26, 2020
Applicants:
National Research Council of Canada, Cephalon, Inc.
Inventors:
Danica Stanimirovic, Traian Sulea, Kristin Kemmerich, David Wilson, Jennifer Stratton, Matthew Pollard, Adam Clarke
Abstract: Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising administering a therapeutically effective dose of reslizumab to the patient whose symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/?L.
Type:
Grant
Filed:
October 13, 2017
Date of Patent:
March 3, 2020
Assignee:
Cephalon, Inc.
Inventors:
Christopher O'Brien, James Zangrilli, Tushar Shah, Guy Brusselle
Abstract: The disclosure provides compounds of Formula (I), wherein X, Y, and Z are defined herein. The disclosure also provides particles comprising one or more compounds described herein, compositions comprising one or more compounds or particles described herein and a pharmaceutically acceptable carrier, and methods of treating a subject in need thereof comprising administering one or more compounds, particles, or compositions described herein to the subject. X—Y—Z??(I).
Abstract: The present disclosure is directed to improved methods useful for the preparation of, for example, 2-[[5-chloro-2-[[(6S)-6-[4-(2-hydroxyethyl)piperazin-1-yl]-1-methoxy-6,7,8,9-tetrahydro-5Hbenzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]-N-methyl-benzamide (CEP-37440).
Type:
Grant
Filed:
December 23, 2015
Date of Patent:
April 16, 2019
Assignee:
CEPHALON, INC.
Inventors:
Shawn P. Allwein, Roger P. Bakale, Dale R. Mowrey, Daniel E. Petrillo, Sander Kluwer
Abstract: The present invention is directed to particles prepared via the polymerization of at least one surfactant and an isocyanate-containing compound. Pharmaceutical compositions prepared using these particles are also described.
Abstract: The present disclosure relates to crystalline forms of 4,5,6,7-tetrahydro-11-methoxy-2-[(4-methyl-1-piperazinyl)methyl]-1H-cyclopenta[a]pyrrolo[3,4-c]carbazole-1,3(2H)-dione, including salts forms and free base forms.
Type:
Grant
Filed:
November 25, 2015
Date of Patent:
December 11, 2018
Assignee:
CEPHALON, INC.
Inventors:
Stephen J. Bierlmaier, Ralph C. Haltiwanger, Martin J. Jacobs
Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.
Type:
Grant
Filed:
September 16, 2016
Date of Patent:
November 27, 2018
Assignee:
Cephalon, Inc.
Inventors:
Lynn Dorothy Poulton, Matthew Pollard, Anthony G. Doyle, Bridget Ann Cooksey, Vanya Pande, Adam William Clarke
Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
Type:
Grant
Filed:
March 7, 2017
Date of Patent:
October 30, 2018
Assignee:
CEPHALON, INC.
Inventors:
Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
Abstract: Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.
Type:
Grant
Filed:
June 17, 2016
Date of Patent:
February 27, 2018
Assignee:
Cephalon, Inc.
Inventors:
Nadine C. Becknell, Reddeppa Reddy Dandu, Bruce D. Dorsey, Dimitar B. Gotchev, Robert L. Hudkins, Linda Weinberg, Craig A. Zificsak, Allison L. Zulli